Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 6.07. Compared to its 3-year average P/B ratio of -5.39, the current P/B ratio is approximately -212.65% higher. Relative to its 5-year average P/B ratio of -5.39, the current P/B ratio is about -212.65% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately 0.47%. Compared to its 3-year average FCF yield of 0.05%, the current FCF yield is approximately 894.98% lower. Relative to its 5-year average FCF yield of 0.05%, the current FCF yield is about 894.98% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GYRE competitors is 1.20, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE.O) exhibits a P/S ratio of 4.17, which is 247.56% above the industry average. Given its robust revenue growth of 19.92%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GYRE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GYRE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GYRE currently overvalued or undervalued?

What is Gyre Therapeutics Inc (GYRE) fair value?

GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Gyre Therapeutics Inc (GYRE) is between 2.83 to 10.96 according to relative valuation method.

How does GYRE's valuation metrics compare to the industry average?

The average P/S ratio for GYRE's competitors is 1.20, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 4.17, which is 247.56% above the industry average. Given its robust revenue growth of 19.92%, this premium appears unsustainable.

What is the current P/B ratio for Gyre Therapeutics Inc (GYRE) as of Mar 03 2026?

As of Mar 03 2026, Gyre Therapeutics Inc (GYRE) has a P/B ratio of 6.07. This indicates that the market values GYRE at 6.07 times its book value.

What is the current FCF Yield for Gyre Therapeutics Inc (GYRE) as of Mar 03 2026?

As of Mar 03 2026, Gyre Therapeutics Inc (GYRE) has a FCF Yield of 0.47%. This means that for every dollar of Gyre Therapeutics Inc's market capitalization, the company generates 0.47 cents in free cash flow.

What is the current Forward P/E ratio for Gyre Therapeutics Inc (GYRE) as of Mar 03 2026?

As of Mar 03 2026, Gyre Therapeutics Inc (GYRE) has a Forward P/E ratio of 31.67. This means the market is willing to pay $31.67 for every dollar of Gyre Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Gyre Therapeutics Inc (GYRE) as of Mar 03 2026?

As of Mar 03 2026, Gyre Therapeutics Inc (GYRE) has a Forward P/S ratio of 4.17. This means the market is valuing GYRE at $4.17 for every dollar of expected revenue over the next 12 months.

GYRE Valuation